Glaxosmithkline Pharmaceuticals Ltd Share Price

2,731.5
(1.56%)
Jul 24, 2024|11:39:53 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open2,716
  • Day's High2,755
  • 52 Wk High2,825
  • Prev. Close2,689.65
  • Day's Low2,697
  • 52 Wk Low1,380.1
  • Turnover (lac)1,554.76
  • P/E69.92
  • Face Value10
  • Book Value105.31
  • EPS38.44
  • Mkt. Cap (Cr.)46,273.26
  • Div. Yield1.19
No Records Found

Glaxosmithkline Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

2,716

Prev. Close

2,689.65

Turnover(Lac.)

1,554.76

Day's High

2,755

Day's Low

2,697

52 Week's High

2,825

52 Week's Low

1,380.1

Book Value

105.31

Face Value

10

Mkt Cap (₹ Cr.)

46,273.26

P/E

69.92

EPS

38.44

Divi. Yield

1.19

Glaxosmithkline Pharmaceuticals Ltd Corporate Action

17 May 2024

12:00 AM

AGM

Announcement Date: 17 May, 2024

arrow

19 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

17 May 2024

12:00 AM

Dividend

Dividend Amount: 32

Record Date: 31 May, 2024

arrow

Glaxosmithkline Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glaxosmithkline Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

24 Jul, 2024|12:01 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 750.00%

Foreign: 75.00%

Indian: 0.00%

Non-Promoter- 11.51%

Institutions: 11.51%

Non-Institutions: 13.48%

Custodian: 0.00%

Share Price

Glaxosmithkline Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

169.41

169.41

169.41

169.41

Preference Capital

0

0

0

0

Reserves

1,614.69

1,583.59

2,508.21

1,327.71

Net Worth

1,784.1

1,753

2,677.62

1,497.12

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

3,217.5

2,920.47

3,224.68

2,871.68

yoy growth (%)

10.17

-9.43

12.29

-1.07

Raw materials

-1,295.73

-1,249.36

-1,307.86

-1,240.75

As % of sales

40.27

42.77

40.55

43.2

Employee costs

-610.23

-616.16

-628.55

-523.39

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

761.86

625.82

646.99

523.78

Depreciation

-68.18

-78.6

-82.67

-37.98

Tax paid

-396.86

-166.53

-212.44

-189.59

Working capital

776.94

111.42

187.45

-365.58

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

10.17

-9.43

12.29

-1.07

Op profit growth

26.44

-9.21

29.5

21.07

EBIT growth

21.37

-3.66

24.68

12.53

Net profit growth

372.78

224.9

-68.73

4.51

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

3,453.71

3,251.72

3,278.03

2,925.6

3,224.38

Excise Duty

0

0

0

0

0

Net Sales

3,453.71

3,251.72

3,278.03

2,925.6

3,224.38

Other Operating Income

0

0

0

0

0

Other Income

122.59

103.71

1,401.31

181.46

79.01

Glaxosmithkline Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,601.6

125.973,84,469.44867.60.845,536.9998.75

Cipla Ltd

CIPLA

1,497.9

32.551,20,921.781,038.40.573,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,527

76.161,19,967.915310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,148.85

33.631,15,601.191,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,865

26.731,14,525.251,034.80.585,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glaxosmithkline Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Independent Director

D Sundaram

Company Sec. & Compli. Officer

A A Nadkarni

Independent Director

P V Bhide

Independent Director

A N Roy

Non Executive Director

Subesh Williams

Chairperson

Renu S Karnad

Independent Director

Sunita Maheshwari

Independent Director

Manu Anand

Managing Director

Bhushan Akshikar

Whole Time Director & CFO

J. Chandy

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Glaxosmithkline Pharmaceuticals Ltd

Summary

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India. The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines, for the prevention of Hepatitis A, Hepatitis B, Invasive Disease caused by H, Influenza, Chickenpox, Diphtheria, Pertussis, Tetanus, Rotavirus, Cervical Cancer and Others. They have two manufacturing units in India, located at Nashik and Thane. Also, they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13, 1924. During year 1956, the Company began primary production of vaccines at Worli. In the year 1960, the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961, the Company started manufactu
Read More

Company FAQs

What is the Glaxosmithkline Pharmaceuticals Ltd share price today?

Down Arrow

The Glaxosmithkline Pharmaceuticals Ltd shares price on N/A is Rs.₹2725.1 today.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glaxosmithkline Pharmaceuticals Ltd is ₹46164.84 Cr. as of 24 Jul ‘24

What is the PE and PB ratio of Glaxosmithkline Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Glaxosmithkline Pharmaceuticals Ltd is 69.92 and 25.52 as of 24 Jul ‘24

What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Glaxosmithkline Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glaxosmithkline Pharmaceuticals Ltd is ₹1381.6 and ₹2825.15 as of 24 Jul ‘24

What is the CAGR of Glaxosmithkline Pharmaceuticals Ltd?

Down Arrow

Glaxosmithkline Pharmaceuticals Ltd's CAGR for 5 Years at 17.39%, 3 Years at 16.92%, 1 Year at 93.04%, 6 Month at 20.80%, 3 Month at 38.35% and 1 Month at 1.90%.

What is the shareholding pattern of Glaxosmithkline Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Glaxosmithkline Pharmaceuticals Ltd is as follows:
Promoters - 75.00 %
Institutions - 11.52 %
Public - 13.48 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.